JCR Pharmaceuticals said on December 24 that it has signed an exclusive license agreement with Italy’s Italfarmaco to bring in givinostat for the treatment of Duchenne muscular dystrophy (DMD) in Japan. Under the deal, JCR obtains exclusive commercialization rights in…
To read the full story
Related Article
- JCR Expects Strong Returns from Recently In-Licensed DMD Drug: CEO
January 26, 2026
BUSINESS
- Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026
- Sawai to End Teribone Generic Sales following Patent Settlement
February 26, 2026
- Darzquro Seen as Emerging Standard in High-Risk SMM: Specialist
February 26, 2026
- Towa Wins Pediatric Autism Use for Abilify Generic
February 26, 2026
- Jardiance Tops Five Promotion Channels in January: Intage
February 26, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





